RhumbLine Advisers’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-4,140
| Closed | -$23.4K | – | 4189 |
|
|
2025
Q1 | $23.4K | Buy |
4,140
+196
| +5% | +$2.51K | ﹤0.01% | 3714 |
|
|
2024
Q4 | $83.2K | Buy |
3,944
+71
| +2% | +$1.63K | ﹤0.01% | 3522 |
|
|
2024
Q3 | $104K | Sell |
3,873
-902
| -19% | -$26.6K | ﹤0.01% | 3485 |
|
|
2024
Q2 | $136K | Buy |
4,775
+951
| +25% | +$33.4K | ﹤0.01% | 3410 |
|
|
2024
Q1 | $162K | Buy |
3,824
+166
| +5% | +$7.46K | ﹤0.01% | 3268 |
|
|
2023
Q4 | $196K | Sell |
3,658
-12
| -0.3% | -$542 | ﹤0.01% | 3196 |
|
|
2023
Q3 | $158K | Buy |
3,670
+214
| +6% | +$9.87K | ﹤0.01% | 3279 |
|
|
2023
Q2 | $190K | Buy |
+3,456
| New | +$190K | ﹤0.01% | 3263 |
|
|
2022
Q2 | – | Sell |
-3,619
| Closed | -$225K | – | 3151 |
|
|
2022
Q1 | $225K | Buy |
3,619
+1,152
| +47% | +$68.1K | ﹤0.01% | 2729 |
|
|
2021
Q4 | $174K | Sell |
2,467
-64
| -3% | -$4.55K | ﹤0.01% | 2862 |
|
|
2021
Q3 | $177K | Buy |
2,531
+180
| +8% | +$14.3K | ﹤0.01% | 2927 |
|
|
2021
Q2 | $196K | Sell |
2,351
-1,948
| -45% | -$138K | ﹤0.01% | 2925 |
|
|
2021
Q1 | $235K | Sell |
4,299
-134
| -3% | -$6.52K | ﹤0.01% | 2784 |
|
|
2020
Q4 | $190K | Buy |
4,433
+806
| +22% | +$30.1K | ﹤0.01% | 2856 |
|
|
2020
Q3 | $109K | Sell |
3,627
-805
| -18% | -$27.1K | ﹤0.01% | 2850 |
|
|
2020
Q2 | $137K | Buy |
+4,432
| New | +$119K | ﹤0.01% | 2884 |
|
|
2019
Q2 | – | Sell |
-4,864
| Closed | -$210K | – | 2985 |
|
|
2019
Q1 | $210K | Sell |
4,864
-27
| -0.6% | -$979 | ﹤0.01% | 2731 |
|
|
2018
Q4 | $156K | Buy |
4,891
+1,584
| +48% | +$62.4K | ﹤0.01% | 2802 |
|
|
2018
Q3 | $174K | Buy |
3,307
+238
| +8% | +$13.4K | ﹤0.01% | 2773 |
|
|
2018
Q2 | $164K | Buy |
+3,069
| New | +$157K | ﹤0.01% | 2783 |
|
|
2016
Q2 | – | Sell |
-4,206
| Closed | -$127K | – | 2997 |
|
|
2016
Q1 | $127K | Buy |
4,206
+473
| +13% | +$13.4K | ﹤0.01% | 2855 |
|
|
2015
Q4 | $130K | Buy |
3,733
+191
| +5% | +$6.53K | ﹤0.01% | 2913 |
|
|
2015
Q3 | $134K | Buy |
3,542
+236
| +7% | +$11K | ﹤0.01% | 2896 |
|
|
2015
Q2 | $188K | Buy |
+3,306
| New | +$188K | ﹤0.01% | 2911 |
|
|
2014
Q2 | – | Sell |
-3,214
| Closed | -$152K | – | 3033 |
|
|
2014
Q1 | $152K | Sell |
3,214
-125
| -4% | -$5.69K | ﹤0.01% | 2855 |
|
|
2013
Q4 | $157K | Sell |
3,339
-1,348
| -29% | -$58.9K | ﹤0.01% | 2888 |
|
|
2013
Q3 | $187K | Buy |
4,687
+5
| +0.1% | +$197 | ﹤0.01% | 2810 |
|
|
2013
Q2 | $168K | Buy |
+4,682
| New | +$179K | ﹤0.01% | 3070 |
|
Other funds holding HBIO
AE
HP
GIM
MIM
RhumbLine Advisers's HBIO Position: Q2 2025 in Review
RhumbLine Advisers sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 4,140 shares — an estimated $23.4K sold.
RhumbLine Advisers first reported a position in HBIO in Q2 2013 and held it in 28 quarters. The position peaked at $235K in Q1 2021. 68 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.
- RhumbLine Advisers reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
- RhumbLine Advisers sold 4,140 Harvard Bioscience shares in Q2 2025, an estimated $23.4K.
- RhumbLine Advisers first reported a position in Harvard Bioscience in Q2 2013 and held it in 28 quarters.
- RhumbLine Advisers's Harvard Bioscience position peaked at $235K in Q1 2021.
- 68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.
Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.